WO2004043386A3 - Molecules preferentially associated with effector t cells and methods of their use - Google Patents

Molecules preferentially associated with effector t cells and methods of their use Download PDF

Info

Publication number
WO2004043386A3
WO2004043386A3 PCT/US2003/035719 US0335719W WO2004043386A3 WO 2004043386 A3 WO2004043386 A3 WO 2004043386A3 US 0335719 W US0335719 W US 0335719W WO 2004043386 A3 WO2004043386 A3 WO 2004043386A3
Authority
WO
WIPO (PCT)
Prior art keywords
effector
cell function
cells
protein kinase
theta
Prior art date
Application number
PCT/US2003/035719
Other languages
French (fr)
Other versions
WO2004043386A2 (en
Inventor
Patricia Rao
Original Assignee
Tolerrx Inc
Patricia Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolerrx Inc, Patricia Rao filed Critical Tolerrx Inc
Priority to CA002505546A priority Critical patent/CA2505546A1/en
Priority to JP2005507126A priority patent/JP2006508191A/en
Priority to EP03783270A priority patent/EP1565218A2/en
Priority to AU2003290688A priority patent/AU2003290688B8/en
Publication of WO2004043386A2 publication Critical patent/WO2004043386A2/en
Publication of WO2004043386A3 publication Critical patent/WO2004043386A3/en
Priority to AU2008202955A priority patent/AU2008202955A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

The present invention is based, at least in part, on the discovery of certain genes which are absent from T regulatory cells and present on effector T cells (Th1 and Th2), e.g., Protein Kinase C Theta (PKC theta). Furthermore, a pathway essential for the production of inflammatory cytokines and cellular proliferation of inflammatory, effector T cells is not utilized by regulatory T cells. Accordingly, in one aspect the invention provides methods for promoting regulatory T cell function in immune cells relative to effector T cell function, comprising contacting immune cells with an agent that inhibits a protein kinase C theta pathway in the immune cells. In another aspect, the invention provides methods for treating a subject having a condition that would benefit from promoting regulatory T cell function relative to effector T cell function in the subject, comprising administering an agent that inhibits a protein kinase C theta pathway in immune cells of the subject. In still another aspect, the invention provides assays for screening compounds that specifically modulate an effector T cell function without modulating regulatory T cell function comprising contacting a protein kinase C theta pathway molecule with a test compound and determining the ability of the test compound to modulate the protein kinase C theta pathway molecule activity, wherein modulation of a protein kinase C theta pathway molecule activity indicates that the test compound is a specific modulator of an effector T cell function.
PCT/US2003/035719 2002-11-08 2003-11-10 Molecules preferentially associated with effector t cells and methods of their use WO2004043386A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002505546A CA2505546A1 (en) 2002-11-08 2003-11-10 Molecules preferentially associated with effector t cells and methods of their use
JP2005507126A JP2006508191A (en) 2002-11-08 2003-11-10 Molecules preferentially associated with effector T cells and uses thereof
EP03783270A EP1565218A2 (en) 2002-11-08 2003-11-10 Molecules preferentially associated with effector t cells and methods of their use
AU2003290688A AU2003290688B8 (en) 2002-11-08 2003-11-10 Molecules preferentially associated with effector T cells and methods of their use
AU2008202955A AU2008202955A1 (en) 2002-11-08 2008-07-03 Molecules perferentially associated with effector T cells and methods of their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42477702P 2002-11-08 2002-11-08
US60/424,777 2002-11-08
US46747703P 2003-05-02 2003-05-02
US60/467,477 2003-05-02

Publications (2)

Publication Number Publication Date
WO2004043386A2 WO2004043386A2 (en) 2004-05-27
WO2004043386A3 true WO2004043386A3 (en) 2004-10-28

Family

ID=32314555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035719 WO2004043386A2 (en) 2002-11-08 2003-11-10 Molecules preferentially associated with effector t cells and methods of their use

Country Status (6)

Country Link
US (1) US20040166099A1 (en)
EP (1) EP1565218A2 (en)
JP (1) JP2006508191A (en)
AU (2) AU2003290688B8 (en)
CA (1) CA2505546A1 (en)
WO (1) WO2004043386A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078948A2 (en) * 2003-03-04 2004-09-16 National Jewish Medical And Research Center METHOD TO IDENTIFY REGULATORS OF CELLULAR ACTIVATION USING Bcl10
WO2005037868A2 (en) * 2003-10-16 2005-04-28 Case Western Reserve University Methods of treating nfat-related disorders
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
WO2010090875A1 (en) 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
WO2010126967A1 (en) * 2009-04-28 2010-11-04 Boehringer Ingelheim International Gmbh Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
CA2780759A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US20110142814A1 (en) * 2009-12-16 2011-06-16 New York University Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
US8710223B2 (en) 2010-07-21 2014-04-29 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2013060328A1 (en) * 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
US9645151B2 (en) 2012-08-17 2017-05-09 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
JP6357167B2 (en) 2012-12-04 2018-07-11 ライジェル ファーマシューティカルズ， インコーポレイテッド Protein kinase C inhibitors and uses thereof
US9169249B2 (en) 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
AU2018363880B2 (en) * 2017-11-08 2022-04-07 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US20020068271A1 (en) * 1999-12-27 2002-06-06 Amnon Altman Methods for identifying agents capable of modulating protein kinase C theta (PKC0) activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US20020068271A1 (en) * 1999-12-27 2002-06-06 Amnon Altman Methods for identifying agents capable of modulating protein kinase C theta (PKC0) activity

Also Published As

Publication number Publication date
AU2003290688B2 (en) 2008-04-03
AU2003290688A1 (en) 2004-06-03
US20040166099A1 (en) 2004-08-26
CA2505546A1 (en) 2004-05-27
WO2004043386A2 (en) 2004-05-27
AU2008202955A1 (en) 2008-07-31
AU2003290688B8 (en) 2008-04-24
JP2006508191A (en) 2006-03-09
EP1565218A2 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
WO2004043386A3 (en) Molecules preferentially associated with effector t cells and methods of their use
EA200702452A1 (en) METHOD OF MODULATION OF STRESS-ACTIVATED PROTEINKINASE SYSTEM
Sethi et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues
Schlage et al. Monitoring matrix metalloproteinase activity at the epidermal–dermal interface by SILAC‐iTRAQ‐TAILS
RU2000110736A (en) A method for modulating the function of serine / threonine protein-based compound AZABENZIMIDAZOLA, methods for identifying compounds that modulate the function of serine / threonine protein kinase method for preventing or treating a pathological condition IN THE BODY-based compound AZABENZIMIDAZOLA, its method of synthesis and pharmaceutical compositions
Zhou et al. Elevated H3K27ac in aged skeletal muscle leads to increase in extracellular matrix and fibrogenic conversion of muscle satellite cells
DE69942459D1 (en) ISOLATED NUCLEIC ACID MOLECULES COPYING T CELLS INDUCIBLE FACTORS (TIF), ENCODING PROTEINS AND THEIR USE
WO2003022028A3 (en) Methods, reagents, kits and apparatus for protein function analysis
EA201070572A1 (en) MODULATION OF TRANSPORT OF PROTEINS
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
NO20044051L (en) Assay for ACTRIIB kinase activity
EA200401453A1 (en) MOLECULES OF CELLULAR RECOGNITION ON CELLULAR SURFACE CONTAINING IMMUNOGLOBULIN DOMAIN
DK1454992T3 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
BR9913190A (en) Modulation of multiple lineage protein kinase
WO2005060722A3 (en) Modulation of immune system function by modulation of polypeptide arginine methyltransferases
ATE548463T1 (en) LRRK2 POLYPEPTIDE SUBSTRATES AND USES THEIR
Eigenbrodt et al. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors.
ATE540966T1 (en) NEW ENZYME SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPERS IN THE DETECTION OF MICROORGANISMS WITH PEPTIDASE ACTIVITY
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2004005881A3 (en) Methods for identification of compounds modulating insulin resistance
ATE527379T1 (en) MODULATION OF HSV INFECTION
WO2008033992A3 (en) High throughput screening assay for histone modifying enzyme modulators
DE60322882D1 (en) T CELL SUBPOPULATION FOR REGULATING DARMIMMUNITY
WO2008005487A3 (en) Peptide sequences for modulation of protein kinase c

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003290688

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2505546

Country of ref document: CA

Ref document number: 2005507126

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003783270

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783270

Country of ref document: EP